The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE).
P. E. Goss
Honoraria - GlaxoSmithKline; Novartis; Pfizer
C. H. Barrios
No relevant relationships to disclose
R. Bell
Consultant or Advisory Role - Amgen
D. Finkelstein
No relevant relationships to disclose
H. Iwata
No relevant relationships to disclose
M. Martin
Consultant or Advisory Role - Amgen
A. H. Braun
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
R. D. Dansey
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
R. E. Coleman
Consultant or Advisory Role - Amgen; Novartis
Honoraria - Amgen; Novartis
Research Funding - Novartis
Expert Testimony - Novartis